Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024:1448:365-383.
doi: 10.1007/978-3-031-59815-9_25.

Kawasaki Disease-Associated Cytokine Storm Syndrome

Affiliations
Review

Kawasaki Disease-Associated Cytokine Storm Syndrome

Paul Tsoukas et al. Adv Exp Med Biol. 2024.

Abstract

Kawasaki disease (KD) is a hyperinflammatory syndrome manifesting as an acute systemic vasculitis characterized by fever, nonsuppurative conjunctival injection, rash, oral mucositis, extremity changes, and cervical lymphadenopathy. KD predominantly affects young children and shares clinical features and immunobiology with other hyperinflammation syndromes including systemic juvenile idiopathic arthritis (sJIA) and multisystem inflammatory syndrome in children (MIS-C). Cytokine storm syndrome (CSS) is an acute complication in ~2% of KD patients; however, the incidence is likely underestimated as many clinical and laboratory features of both diseases overlap. CSS should be entertained when a child with KD is unresponsive to IVIG therapy with recalcitrant fever. Early recognition and prompt institution of immunomodulatory treatment can substantially reduce the mortality and morbidity of CSS in KD. Given the known pathogenetic role of IL-1β in both syndromes, the early use of IL-1 blockers in refractory KD with CSS deserves consideration.

Keywords: Cytokine storm syndrome; Hyperinflammation; Kawasaki disease; Macrophage activation syndrome; Multisystem inflammatory syndrome in children; Systemic juvenile idiopathic arthritis.

PubMed Disclaimer

References

    1. Newburger Jane W, Takahashi M, Burns Jane C. Kawasaki disease. J Am Coll Cardiol. 2016;67(14):1738–49. - PubMed - DOI
    1. McCrindle BW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927–99. - PubMed - DOI
    1. Kawasaki T. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi. 1967;16(3):178–222.
    1. Newburger JW, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315(6):341–7. - PubMed - DOI
    1. Kuramochi Y, et al. Hemodynamic factors of thrombus formation in coronary aneurysms associated with Kawasaki disease. Pediatr Int. 2000;42(5):470–5. - PubMed - DOI

MeSH terms

LinkOut - more resources